Viking Therapeutics Files 8-K
Ticker: VKTX · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1607678
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
Related Tickers: VKTX
TL;DR
Viking Therapeutics filed an 8-K on 3/4/24. No major news, just standard filings.
AI Summary
Viking Therapeutics, Inc. filed an 8-K on March 4, 2024, to report other events and financial statements. The filing does not contain specific financial figures or details about new events, but serves as a notification of these items being filed.
Why It Matters
This filing indicates that Viking Therapeutics has submitted important corporate updates and financial information to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for other events and financial statements, with no specific new material information disclosed within the provided text.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- March 4, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 9920 Pacific Heights Blvd , Suite 350 , San Diego , California 92121 (address) — Principal Executive Offices
- 858-704-4660 (phone_number) — Registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Viking Therapeutics, Inc.?
The purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of March 4, 2024.
When was this 8-K filing submitted?
The 8-K filing was submitted on March 4, 2024.
What is the state of incorporation for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Viking Therapeutics, Inc.?
The principal executive office address is 9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121.
Does this filing contain specific financial results or new material events?
Based on the provided text, this filing serves as a notification of 'Other Events' and 'Financial Statements and Exhibits' being filed, but does not detail specific financial results or new material events within this excerpt.
Filing Stats: 492 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-03-04 16:52:52
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
- $85.00 — mon stock at a public offering price of $85.00 per share, which included the exercise
Filing Documents
- vktx-20240304.htm (8-K) — 44KB
- vktx-ex99_1.htm (EX-99.1) — 18KB
- img201808844_0.jpg (GRAPHIC) — 11KB
- 0000950170-24-024878.txt ( ) — 199KB
- vktx-20240304.xsd (EX-101.SCH) — 30KB
- vktx-20240304_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On March 4, 2024, Viking Therapeutics, Inc. (the "Company") issued a press release announcing the closing of its previously announced underwritten public offering of shares of its common stock. In the offering, the Company sold an aggregate of 7,441,650 shares of its common stock at a public offering price of $85.00 per share, which included the exercise in full by the underwriters of their option to purchase 970,650 additional shares of common stock. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated March 4, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIKING THERAPEUTICS, INC. Date: March 4, 2024 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)